From: The effectiveness of Reslizumab in severe asthma treatment: a real-world experience

Variables | Baseline (N=26) | 12 weeks (N=24) | 1 year (N=22) | 2 year2 (N=11) |
---|---|---|---|---|

Mean ACQ-6 score ± SD | 3.50 ± 1.1 | 1.8 ± 1.7 | 1.7 ± 1.4 | 1.3 ± 1.1 |

Mean improvement in ACQ-6 | — | 1.7 | 1.7 | 2.0 |

P value | — | <0.0001 | 0.0001 | 0.0001 |

Mean glucocorticoid dose^{a} ± SD | 9.29 ± 4.32 | 4.79 ± 4.07 | 4.77 ± 4.53 | 4.62 ± 3.59 |

Median reduction in the final oral glucocorticoid-% of baseline value | — | 50% | 50% | 50% |

Mean reduction of prednisolone dose ± SD | — | 4.50 ± 3.85 | 5.23 ± 4.80 | 4.12 ± 4.06 |

P Value | — | 0.0008 | 0.0048 | 0.0239 |

Mean percent of FEV_{1} predicted value (before bronchodilation) +- SD | 62.08% ± 19.85 | 64.51% ± 25.30 | 70.61% ± 15.40 | 74.91 ± 22.63 |

Mean improvement in FEV1 percent of predicted value | — | 6.28 | 11.95 | 12.14 |

P value | — | 0.36 | 0.018 | 0.0021 |

Average number of exacerbations^{b} ± SD | 8.32 ± 4.68 | — | 1.74 ± 2.13 | 0.91 ± 0.70 |

Mean reduction in annual Exacerbations^{b} ± SD | — | — | 7.26 ± 4.74 | 6.64 ± 3.29 |

P Value | — | — | <0.0001 | <0.0001 |

Mean peripheral blood Eosinophils count^{c} ± SD | 0.78 ± 0.51 | 0.05 ± 0.03 | 0.05 ± 0.04 | 0.04 ± 0.03 |

Mean reduction of eosinophils counts | — | 0.73 ± 0.52 | 0.74 ± 0.57 | 0.72 ± 0.63 |

P Value | — | <0.0001 | <0.0001 | 0.0057 |